Agency Information Collection Activities; Proposed Collection; Comment Request; Prescription Drug Marketing Act of 1987; Administrative Procedures, Policies, and Requirements, 68273-68275 [2014-26917]

Download as PDF Federal Register / Vol. 79, No. 220 / Friday, November 14, 2014 / Notices beneficiaries and to educate beneficiaries about the process. If a prior authorization request is not affirmed, and the claim is still submitted by the provider/supplier, the claim will be denied in full, but beneficiaries will continue to have all applicable administrative appeal rights. Only one prior authorization request per beneficiary per designated time period can be provisionally affirmed. If the initial provider/supplier cannot complete the total number of prior authorized transports (for example, the initial ambulance company closes or no longer services that area), the initial request is cancelled. In this situation, a subsequent prior authorization request may be submitted for the same beneficiary and must include the required documentation in the submission. If multiple ambulance providers/suppliers are providing transports to the beneficiary during the same or overlapping time period, the prior authorization decision will only cover the provider/supplier indicated in the provisionally affirmed prior authorization request. Any provider/ supplier submitting claims for repetitive scheduled nonemergent ambulance transports for which no prior authorization request is recorded will be subject to 100 percent prepayment medical review of those claims. Additional information is available on the CMS Web site at http://go.cms.gov/ PAAmbulance. III. Collection of Information Requirements Section 1115A(d)(3) of the Act, as added by section 3021 of the Affordable Care Act, states that chapter 35 of title 44, United States Code (the Paperwork Reduction Act of 1995), shall not apply to the testing and evaluation of models or expansion of such models under this section. Consequently, this document need not be reviewed by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 35). mstockstill on DSK4VPTVN1PROD with NOTICES Authority: Section 1115A of the Social Security Act. Dated: October 8, 2014. Marilyn Tavenner, Administrator, Centers for Medicare & Medicaid Services. [FR Doc. 2014–26987 Filed 11–13–14; 8:45 am] BILLING CODE 4120–01–P VerDate Sep<11>2014 17:37 Nov 13, 2014 Jkt 235001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2011–N–0279] Agency Information Collection Activities; Proposed Collection; Comment Request; Prescription Drug Marketing Act of 1987; Administrative Procedures, Policies, and Requirements AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection in the regulations on the Prescription Drug Marketing Act of 1987; Administrative Procedures, Policies, and Requirements. DATES: Submit either electronic or written comments on the collection of information by January 13, 2015. ADDRESSES: Submit electronic comments on the collection of information to: http:// www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA 305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE–14526, Silver Spring, MD 20993–0002, PRAStaff@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. SUMMARY: PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 68273 Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Prescription Drug Marketing Act of 1987; Administrative Procedures, Policies, and Requirements—21 CFR Part 203—(OMB Control Number 0910– 0435)—Extension FDA is requesting OMB approval under the PRA (44 U.S.C. 3501–3520) for the reporting and recordkeeping requirements contained in the regulations implementing the Prescription Drug Marketing Act of 1987 (PDMA). PDMA was intended to ensure that drug products purchased by consumers are safe and effective and to avoid an unacceptable risk that counterfeit, adulterated, misbranded, subpotent, or expired drugs are sold. PDMA was enacted by Congress because there were insufficient safeguards in the drug distribution system to prevent the introduction and retail sale of substandard, ineffective, or counterfeit drugs, and that a wholesale drug diversion submarket had developed that prevented effective control over the true sources of drugs. Congress found that large amounts of drugs had been reimported into the United States as U.S. goods returned causing a health and safety risk to U.S. consumers because the drugs may become subpotent or adulterated during foreign handling and shipping. Congress also found that a ready market for prescription drug reimports had been the catalyst for a continuing series of E:\FR\FM\14NON1.SGM 14NON1 68274 Federal Register / Vol. 79, No. 220 / Friday, November 14, 2014 / Notices frauds against U.S. manufacturers and had provided the cover for the importation of foreign counterfeit drugs. Congress also determined that the system of providing drug samples to physicians through manufacturers’ representatives had resulted in the sale to consumers of misbranded, expired, and adulterated pharmaceuticals. The bulk resale of below-wholesale priced prescription drugs by health care entities for ultimate sale at retail also helped to fuel the diversion market and was an unfair form of competition to wholesalers and retailers who had to pay otherwise prevailing market prices. FDA is requesting OMB approval for the following existing reporting and recordkeeping requirements: TABLE 1—REPORTING REQUIREMENTS 21 CFR section Requirement 203.11 ............................................. 203.30(a)(1) and (b) ........................ 203.30(a)(3), (a)(4), and (c) ............ 203.31(a)(1) and (b) ........................ 203.31(a)(3), (a)(4), and (c) ............ 203.37(a) ......................................... 203.37(b) ......................................... 203.37(c) ......................................... 203.37(d) ......................................... 203.39(g) ......................................... Applications for re-importation to provide emergency medical care. Drug sample requests (drug samples distributed by mail or common carrier). Drug sample receipts (receipts for drug samples distributed by mail or common carrier). Drug sample requests (drug samples distributed by means other than the mail or a common carrier). Drug sample receipts (drug samples distributed by means other than the mail or a common carrier). Investigation of falsification of drug sample records. Investigation of a significant loss or known theft of drug samples. Notification that a representative has been convicted of certain offenses involving drug samples. Notification of the individual responsible for responding to a request for information about drug samples. Preparation by a charitable institution of a reconciliation report for donated drug samples. TABLE 2—RECORDKEEPING REQUIREMENTS 21 CFR section Requirement 203.23(a) and (b) ............................ 203.23(c) ......................................... 203.30(a)(2) and 203.31(a)(2) ........ Credit memo for returned drugs. Documentation of proper storage, handling, and shipping conditions for returned drugs. Verification that a practitioner requesting a drug sample is licensed or authorized by the appropriate State authority to prescribe the product. Contents of the inventory record and reconciliation report required for drug samples distributed by representatives. Investigation of apparent discrepancies and significant losses revealed through the reconciliation report. Lists of manufacturers’ and distributors’ representatives. Written policies and procedures describing administrative systems. Report of investigation of falsification of drug sample records. Report of investigation of significant loss or known theft of drug samples. Records of drug sample distribution identifying lot or control numbers of samples distributed. (The information collection in 21 CFR 203.38(b) is already approved under OMB control number 0910–0139). Records of drug samples destroyed or returned by a charitable institution. Record of drug samples donated to a charitable institution. Records of donation and distribution or other disposition of donated drug samples. Inventory and reconciliation of drug samples donated to charitable institutions. Drug origin statement. Retention of drug origin statement for 3 years. List of authorized distributors of record. 203.31(d)(1) and (d)(2) ................... 203.31(d)(4) .................................... 203.31(e) ......................................... 203.34 ............................................. 203.37(a) ......................................... 203.37(b) ......................................... 203.38(b) ......................................... 203.39(d) ......................................... 203.39(e) ......................................... 203.39(f) .......................................... 203.39(g) ......................................... 203.50(a) ......................................... 203.50(b) ......................................... 203.50(d) ......................................... mstockstill on DSK4VPTVN1PROD with NOTICES The reporting and recordkeeping requirements are intended to help achieve the following goals: (1) To ban the reimportation of prescription drugs produced in the United States, except when reimported by the manufacturer or under FDA authorization for emergency medical care; (2) to ban the sale, purchase, or trade, or the offer to sell, purchase, or trade, of any prescription drug sample; (3) to limit the distribution of drug samples to practitioners licensed or authorized to prescribe such drugs or to pharmacies of hospitals or other health care entities at the request of a licensed or authorized practitioner; (4) to require licensed or authorized practitioners to request prescription drug samples in writing; (5) to mandate storage, handling, and recordkeeping requirements for prescription drug samples; (6) to prohibit, with certain exceptions, the sale, purchase, or trade of, or the offer to sell, purchase, or trade, prescription drugs that were purchased by hospitals or other health care entities, or which were donated or supplied at a reduced price to a charitable organization; (7) to require unauthorized wholesale distributors to provide, prior to the wholesale distribution of a prescription drug to another wholesale distributor or retail pharmacy, a statement identifying each prior sale, purchase, or trade of the drug. FDA estimates the burden of this collection of information as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents 21 CFR section 203.11 Re-importation ............................................. 203.30(a)(1) and (b) Drug sample requests ............ VerDate Sep<11>2014 17:37 Nov 13, 2014 Jkt 235001 PO 00000 Number of responses per respondent 1 61,961 Frm 00066 Fmt 4703 Total annual respondents 1 12 Sfmt 4703 1 743,532 E:\FR\FM\14NON1.SGM Average burden per response .50 (30 minutes) ........ .06 (4 minutes) .......... 14NON1 Total hours 1 44,612 Federal Register / Vol. 79, No. 220 / Friday, November 14, 2014 / Notices 68275 TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Number of responses per respondent Number of respondents 21 CFR section Total annual respondents Average burden per response Total hours 203.30(a)(3), (a)(4), (c) Drug sample receipts ........ 203.31(a)(1) and (b) Drug sample requests ............ 203.31(a)(3), (a)(4),(c) Drug sample receipts .......... 203.37(a) Falsification of records ............................ 203.37(b) Loss or theft of samples .......................... 203.37(c) Convictions .............................................. 203.37(d) Contact person ........................................ 203.39(g) Reconciliation report ................................ 61,961 232,355 232,355 50 50 1 50 1 12 135 135 4 40 1 1 1 743,532 31,367,925 31,367,925 200 2000 1 50 1 .06 (4 minutes) .......... .04 (2 minutes) .......... .03 (2 minutes) .......... .25 (15 minutes) ........ .25 (15 minutes) ........ 1 ................................ .08 (5 minutes) .......... 1 ................................ 44,612 1,254,717 941,038 50 500 1 4 1 Total .................................................................. ........................ ........................ ........................ .................................... 2,285,536 1 There are no capital costs or operating and maintenance costs associated with this collection of information. TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1 Number of recordkeepers 21 CFR section Number of records per recordkeeper Total annual records Average burden per record-keeping Total hours 203.23(a) and (b) Returned drugs ........................... 203.23(c) Returned drugs documentation ............... 203.30(a)(2) and 203.31(a)(2) Practitioner verification. 203.31(d)(1) and (d)(2) Inventory record and reconciliation report. 203.31(d)(4) Investigation of discrepancies and losses. 203.31(e) Representatives lists ............................... 203.34 Administrative systems ................................ 203.37(a) Falsification of drug sample records ....... 203.37(b) Loss or theft of drug samples ................. 203.39(d) Destroyed or returned drug samples ...... 203.39(e) Donated drug samples ............................ 203.39(f) Distribution of donated drug samples ...... 203.39(g) Drug samples donated to charitable institutions. 203.50(a) Drug origin statement .............................. 203.50(b) Drug origin statement retention ............... 203.50(d) Authorized distributors of record ............. 31,676 31,676 2,208 5 5 100 158,380 158,380 220,800 .25 (15 minutes) ........ .08 (5 minutes) .......... .50 (30 minutes) ........ 39,595 12,670 110,400 2,208 1 2,208 40 .............................. 88,320 442 1 442 24 .............................. 10,608 2,208 90 50 50 65 3,221 3,221 3,221 1 1 4 40 1 1 1 1 2,208 90 200 2000 65 3,221 3,221 3,221 1 ................................ 40 .............................. 6 ................................ 6 ................................ 1 ................................ .50 (30 minutes) ........ 8 ................................ 8 ................................ 2,208 3,600 1200 12,000 65 1,611 25,768 25,768 125 125 691 100 100 1 12,500 12,500 691 .17 (10 minutes) ........ .50 (30 minutes) ........ 2 ................................ 2,125 6,250 1,382 Total .................................................................. ........................ ........................ ........................ .................................... 343,570 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Dated: November 7, 2014. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2014–26917 Filed 11–13–14; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration mstockstill on DSK4VPTVN1PROD with NOTICES [Docket No. FDA–2013–N–0878] Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notification for a New Dietary Ingredient AGENCY: Food and Drug Administration, HHS. ACTION: Notice. VerDate Sep<11>2014 17:37 Nov 13, 2014 Jkt 235001 The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the procedure by which a manufacturer or distributor of a new dietary ingredient or of a dietary supplement containing a new dietary ingredient is to submit to FDA information upon which it has based its conclusion that a dietary supplement containing the new dietary ingredient will reasonably be expected SUMMARY: PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 to be safe. The notice also invites comments on two new forms FDA is developing to allow manufacturers and distributors to submit this information electronically via FDA’s Unified Registration and Listing System (FURLS). Submit either electronic or written comments on the collection of information by January 13, 2015. DATES: Submit electronic comments on the collection of information to http:// www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the ADDRESSES: E:\FR\FM\14NON1.SGM 14NON1

Agencies

[Federal Register Volume 79, Number 220 (Friday, November 14, 2014)]
[Notices]
[Pages 68273-68275]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-26917]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0279]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Prescription Drug Marketing Act of 1987; 
Administrative Procedures, Policies, and Requirements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the Agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal Agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information, 
including each proposed extension of an existing collection of 
information, and to allow 60 days for public comment in response to the 
notice. This notice solicits comments on the information collection in 
the regulations on the Prescription Drug Marketing Act of 1987; 
Administrative Procedures, Policies, and Requirements.

DATES: Submit either electronic or written comments on the collection 
of information by January 13, 2015.

ADDRESSES: Submit electronic comments on the collection of information 
to: http://www.regulations.gov. Submit written comments on the 
collection of information to the Division of Dockets Management (HFA 
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, 
Rockville, MD 20852. All comments should be identified with the docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, 
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver 
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
Agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes Agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal Agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, 
before submitting the collection to OMB for approval. To comply with 
this requirement, FDA is publishing notice of the proposed collection 
of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Prescription Drug Marketing Act of 1987; Administrative Procedures, 
Policies, and Requirements--21 CFR Part 203--(OMB Control Number 0910-
0435)--Extension

    FDA is requesting OMB approval under the PRA (44 U.S.C. 3501-3520) 
for the reporting and recordkeeping requirements contained in the 
regulations implementing the Prescription Drug Marketing Act of 1987 
(PDMA). PDMA was intended to ensure that drug products purchased by 
consumers are safe and effective and to avoid an unacceptable risk that 
counterfeit, adulterated, misbranded, subpotent, or expired drugs are 
sold.
    PDMA was enacted by Congress because there were insufficient 
safeguards in the drug distribution system to prevent the introduction 
and retail sale of substandard, ineffective, or counterfeit drugs, and 
that a wholesale drug diversion submarket had developed that prevented 
effective control over the true sources of drugs.
    Congress found that large amounts of drugs had been reimported into 
the United States as U.S. goods returned causing a health and safety 
risk to U.S. consumers because the drugs may become subpotent or 
adulterated during foreign handling and shipping. Congress also found 
that a ready market for prescription drug reimports had been the 
catalyst for a continuing series of

[[Page 68274]]

frauds against U.S. manufacturers and had provided the cover for the 
importation of foreign counterfeit drugs.
    Congress also determined that the system of providing drug samples 
to physicians through manufacturers' representatives had resulted in 
the sale to consumers of misbranded, expired, and adulterated 
pharmaceuticals.
    The bulk resale of below-wholesale priced prescription drugs by 
health care entities for ultimate sale at retail also helped to fuel 
the diversion market and was an unfair form of competition to 
wholesalers and retailers who had to pay otherwise prevailing market 
prices.
    FDA is requesting OMB approval for the following existing reporting 
and recordkeeping requirements:

                     Table 1--Reporting Requirements
------------------------------------------------------------------------
          21 CFR section                         Requirement
------------------------------------------------------------------------
203.11............................  Applications for re-importation to
                                     provide emergency medical care.
203.30(a)(1) and (b)..............  Drug sample requests (drug samples
                                     distributed by mail or common
                                     carrier).
203.30(a)(3), (a)(4), and (c).....  Drug sample receipts (receipts for
                                     drug samples distributed by mail or
                                     common carrier).
203.31(a)(1) and (b)..............  Drug sample requests (drug samples
                                     distributed by means other than the
                                     mail or a common carrier).
203.31(a)(3), (a)(4), and (c).....  Drug sample receipts (drug samples
                                     distributed by means other than the
                                     mail or a common carrier).
203.37(a).........................  Investigation of falsification of
                                     drug sample records.
203.37(b).........................  Investigation of a significant loss
                                     or known theft of drug samples.
203.37(c).........................  Notification that a representative
                                     has been convicted of certain
                                     offenses involving drug samples.
203.37(d).........................  Notification of the individual
                                     responsible for responding to a
                                     request for information about drug
                                     samples.
203.39(g).........................  Preparation by a charitable
                                     institution of a reconciliation
                                     report for donated drug samples.
------------------------------------------------------------------------



                   Table 2--Recordkeeping Requirements
------------------------------------------------------------------------
          21 CFR section                         Requirement
------------------------------------------------------------------------
203.23(a) and (b).................  Credit memo for returned drugs.
203.23(c).........................  Documentation of proper storage,
                                     handling, and shipping conditions
                                     for returned drugs.
203.30(a)(2) and 203.31(a)(2).....  Verification that a practitioner
                                     requesting a drug sample is
                                     licensed or authorized by the
                                     appropriate State authority to
                                     prescribe the product.
203.31(d)(1) and (d)(2)...........  Contents of the inventory record and
                                     reconciliation report required for
                                     drug samples distributed by
                                     representatives.
203.31(d)(4)......................  Investigation of apparent
                                     discrepancies and significant
                                     losses revealed through the
                                     reconciliation report.
203.31(e).........................  Lists of manufacturers' and
                                     distributors' representatives.
203.34............................  Written policies and procedures
                                     describing administrative systems.
203.37(a).........................  Report of investigation of
                                     falsification of drug sample
                                     records.
203.37(b).........................  Report of investigation of
                                     significant loss or known theft of
                                     drug samples.
203.38(b).........................  Records of drug sample distribution
                                     identifying lot or control numbers
                                     of samples distributed. (The
                                     information collection in 21 CFR
                                     203.38(b) is already approved under
                                     OMB control number 0910-0139).
203.39(d).........................  Records of drug samples destroyed or
                                     returned by a charitable
                                     institution.
203.39(e).........................  Record of drug samples donated to a
                                     charitable institution.
203.39(f).........................  Records of donation and distribution
                                     or other disposition of donated
                                     drug samples.
203.39(g).........................  Inventory and reconciliation of drug
                                     samples donated to charitable
                                     institutions.
203.50(a).........................  Drug origin statement.
203.50(b).........................  Retention of drug origin statement
                                     for 3 years.
203.50(d).........................  List of authorized distributors of
                                     record.
------------------------------------------------------------------------

    The reporting and recordkeeping requirements are intended to help 
achieve the following goals: (1) To ban the reimportation of 
prescription drugs produced in the United States, except when 
reimported by the manufacturer or under FDA authorization for emergency 
medical care; (2) to ban the sale, purchase, or trade, or the offer to 
sell, purchase, or trade, of any prescription drug sample; (3) to limit 
the distribution of drug samples to practitioners licensed or 
authorized to prescribe such drugs or to pharmacies of hospitals or 
other health care entities at the request of a licensed or authorized 
practitioner; (4) to require licensed or authorized practitioners to 
request prescription drug samples in writing; (5) to mandate storage, 
handling, and recordkeeping requirements for prescription drug samples; 
(6) to prohibit, with certain exceptions, the sale, purchase, or trade 
of, or the offer to sell, purchase, or trade, prescription drugs that 
were purchased by hospitals or other health care entities, or which 
were donated or supplied at a reduced price to a charitable 
organization; (7) to require unauthorized wholesale distributors to 
provide, prior to the wholesale distribution of a prescription drug to 
another wholesale distributor or retail pharmacy, a statement 
identifying each prior sale, purchase, or trade of the drug.
    FDA estimates the burden of this collection of information as 
follows:

                                                      Table 1--Estimated Annual Reporting Burden 1
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                 Number of
               21 CFR section                    Number of     responses per   Total annual          Average burden  per response           Total hours
                                                respondents     respondent      respondents
--------------------------------------------------------------------------------------------------------------------------------------------------------
203.11 Re-importation.......................               1               1               1  .50 (30 minutes)..........................               1
203.30(a)(1) and (b) Drug sample requests...          61,961              12         743,532  .06 (4 minutes)...........................          44,612

[[Page 68275]]

 
203.30(a)(3), (a)(4), (c) Drug sample                 61,961              12         743,532  .06 (4 minutes)...........................          44,612
 receipts.
203.31(a)(1) and (b) Drug sample requests...         232,355             135      31,367,925  .04 (2 minutes)...........................       1,254,717
203.31(a)(3), (a)(4),(c) Drug sample                 232,355             135      31,367,925  .03 (2 minutes)...........................         941,038
 receipts.
203.37(a) Falsification of records..........              50               4             200  .25 (15 minutes)..........................              50
203.37(b) Loss or theft of samples..........              50              40            2000  .25 (15 minutes)..........................             500
203.37(c) Convictions.......................               1               1               1  1.........................................               1
203.37(d) Contact person....................              50               1              50  .08 (5 minutes)...........................               4
203.39(g) Reconciliation report.............               1               1               1  1.........................................               1
                                             -----------------------------------------------------------------------------------------------------------
    Total...................................  ..............  ..............  ..............  ..........................................       2,285,536
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.


                                                    Table 2--Estimated Annual Recordkeeping Burden 1
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                 Number of
               21 CFR section                    Number of      records per    Total annual        Average burden per record-keeping        Total hours
                                               recordkeepers   recordkeeper       records
--------------------------------------------------------------------------------------------------------------------------------------------------------
203.23(a) and (b) Returned drugs............          31,676               5         158,380  .25 (15 minutes)..........................          39,595
203.23(c) Returned drugs documentation......          31,676               5         158,380  .08 (5 minutes)...........................          12,670
203.30(a)(2) and 203.31(a)(2) Practitioner             2,208             100         220,800  .50 (30 minutes)..........................         110,400
 verification.
203.31(d)(1) and (d)(2) Inventory record and           2,208               1           2,208  40........................................          88,320
 reconciliation report.
203.31(d)(4) Investigation of discrepancies              442               1             442  24........................................          10,608
 and losses.
203.31(e) Representatives lists.............           2,208               1           2,208  1.........................................           2,208
203.34 Administrative systems...............              90               1              90  40........................................           3,600
203.37(a) Falsification of drug sample                    50               4             200  6.........................................            1200
 records.
203.37(b) Loss or theft of drug samples.....              50              40            2000  6.........................................          12,000
203.39(d) Destroyed or returned drug samples              65               1              65  1.........................................              65
203.39(e) Donated drug samples..............           3,221               1           3,221  .50 (30 minutes)..........................           1,611
203.39(f) Distribution of donated drug                 3,221               1           3,221  8.........................................          25,768
 samples.
203.39(g) Drug samples donated to charitable           3,221               1           3,221  8.........................................          25,768
 institutions.
203.50(a) Drug origin statement.............             125             100          12,500  .17 (10 minutes)..........................           2,125
203.50(b) Drug origin statement retention...             125             100          12,500  .50 (30 minutes)..........................           6,250
203.50(d) Authorized distributors of record.             691               1             691  2.........................................           1,382
                                             -----------------------------------------------------------------------------------------------------------
    Total...................................  ..............  ..............  ..............  ..........................................         343,570
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.


    Dated: November 7, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-26917 Filed 11-13-14; 8:45 am]
BILLING CODE 4164-01-P